Page 1 | Search Results | Blood | American Society of Hematology

1-19 of 19

Sort by

Sort Order Select

Journal Articles

Phase Ib/II Study of CPX-351 in Combination with Venetoclax in Patients with Newly Diagnosed, High Risk Acute Myeloid Leukemia

Emmanuel Almanza, Wei-Ying Jen, Courtney D. DiNardo, Kelly S. Chien, Danielle Hammond, Yesid Alvarado Valero, Naveen Pemmaraju, Lucia Masarova, Sherry Pierce, Naval Daver, Alex Bataller, Guillermo Garcia-Manero, Amin M. Alousi, Nicholas J. Short, Farhad Ravandi, Hagop M. Kantarjian, Tapan M. Kadia

Blood (2024) 144 (Supplement 1): 1511.

https://doi.org/10.1182/blood-2024-209558

Published: 2024

Journal Articles

Final Results of a Phase II Study of Uproleselan Combined with Cladribine and Low-Dose Cytarabine for Patients with Treated Secondary Acute Myeloid Leukemia (ts-AML)

Caitlin R Rausch, Emmanuel Almanza-Huante, Wei-Ying Jen, Guillermo Montalban-Bravo, Farhad Ravandi, Kelly S. Chien, Nicholas J. Short, Naval Daver, Courtney D. DiNardo, Abhishek Maiti, Joseph E. Jabbour, Ghayas C. Issa, Guillermo Garcia-Manero, Hagop M. Kantarjian, Tapan M. Kadia

Blood (2024) 144 (Supplement 1): 4262.

https://doi.org/10.1182/blood-2024-203831

Published: 2024

Journal Articles

Performance of the Molecular International Prognostic Scoring System (IPSS-M) in Myelodysplastic Syndromes Treated with Hypomethylating Agent-Based Therapy: A Multicenter Analysis

Blood (2024) 144 (Supplement 1): 4584.

https://doi.org/10.1182/blood-2024-210646

Published: 2024

Journal Articles

Combination of CPX-351 and Gemtuzumab Ozogamicin (GO) in Relapsed Refractory (R/R) Acute Myeloid Leukemia and Post Hypomethylating Agent (HMA) Failure High-Risk Myelodysplastic Syndrome (HR-MDS)

Blood (2024) 144 (Supplement 1): 2903.

https://doi.org/10.1182/blood-2024-207962

Published: 2024

Journal Articles

Patterns of Relapse Following Venetoclax-Based Therapies of Differing Intensity in Acute Myeloid Leukemia

Naszrin Arani, Wei-Ying Jen, Alex Bataller, Alexandre Bazinet, Farhad Ravandi, Naval Daver, Koichi Takahashi, Sanam Loghavi, Hussein A. Abbas, Emmanuel Almanza, Guillermo Montalban-Bravo, Guillermo Garcia-Manero, Courtney D. DiNardo, Hagop M. Kantarjian, Tapan M. Kadia

Blood (2024) 144 (Supplement 1): 4293.

https://doi.org/10.1182/blood-2024-202577

Published: 2024

Journal Articles

Clinicopathologic Predictors of Hypomethylating Agent Failure in Patients with Myelodysplastic Syndromes

Blood (2023) 142 (Supplement 1): 4616.

https://doi.org/10.1182/blood-2023-182256

Published: 2023

Journal Articles

Patterns of Relapse in Patients with Acute Myeloid Leukemia (AML) Treated with Venetoclax-Containing Regimens

Naszrin Arani, Emmanuel Almanza, Alex Bataller, Courtney D. DiNardo, Farhad Ravandi, Naval Daver, Naveen Pemmaraju, Musa Yilmaz, Abhishek Maiti, Patrick K Reville, Sanam Loghavi, Hussein A Abbas, Guillermo Garcia-Manero, Nicholas J. Short, Hagop M. Kantarjian, Tapan M. Kadia

Blood (2023) 142 (Supplement 1): 4236.

https://doi.org/10.1182/blood-2023-191181

Published: 2023

Journal Articles

NPM1-Mutated Myeloid Neoplasms: Updated Outcomes with High-Intensive Chemotherapy Regardless of the Blast Percentage

Georgina Gener-Ricos, Alex Bataller, Emmanuel Almanza-Huante, Kelly S. Chien, Danielle E. Hammond, Koji Sasaki, Courtney D. DiNardo, Tapan M. Kadia, Naval Daver, Gautam Borthakur, Ghayas C. Issa, Nicholas J. Short, Guillermo Garcia-Manero, Guillermo Montalban-Bravo

Blood (2023) 142 (Supplement 1): 957.

https://doi.org/10.1182/blood-2023-187676

Published: 2023

Journal Articles

Clinical Characteristics and Outcomes of Therapy-Related Chronic Myelomonocytic Leukemia: Analysis of a Large Cohort

Alex Bataller, Georgina Gener-Ricos, Emmanuel Almanza, Samuel Urrutia, Kelly S. Chien, Danielle E. Hammond, Koji Sasaki, Courtney D. DiNardo, Farhad Ravandi, Gautam Borthakur, Tapan M. Kadia, Rashmi Kanagal-Shamanna, Hagop M. Kantarjian, Guillermo Garcia-Manero, Guillermo Montalban-Bravo

Blood (2023) 142 (Supplement 1): 3237.

https://doi.org/10.1182/blood-2023-179979

Published: 2023

Journal Articles

Performance of the Molecular International Prognostic Scoring System (IPSS-M) in Hypomethylating Agent-Treated Patients with Myelodysplastic Syndromes

Blood (2023) 142 (Supplement 1): 1857.

https://doi.org/10.1182/blood-2023-189557

Published: 2023

Journal Articles

Uproleselan Added to Cladribine Plus Low Dose Cytarabine (LDAC) in Patients with Treated Secondary Acute Myeloid Leukemia (TS-AML)

Emmanuel Almanza Huante, Alex Bataller, Danielle E. Hammond, Kelly S. Chien, Courtney D. DiNardo, Nicholas J. Short, Abhishek Maiti, Guillermo Montalban-Bravo, Farhad Ravandi, Guillermo Garcia-Manero, Tapan M. Kadia

Blood (2023) 142 (Supplement 1): 2922.

https://doi.org/10.1182/blood-2023-185191

Published: 2023

Journal Articles

Fludarabine, Cytarabine (ARA-C) and Pegylated Erwinase (PEGCRISANTASPASE) in Patients with Relapsed or Refractory Leukemia

Emmanuel Almanza, Alex Bataller, Guillermo Garcia-Manero, Abhishek Maiti, Guillermo Montalban-Bravo, Koichi Takahashi, Nicholas J. Short, Elias Jabbour, Farhad Ravandi, Yesid Alvarado Valero, Tapan M. Kadia

Blood (2023) 142 (Supplement 1): 5971.

https://doi.org/10.1182/blood-2023-191239

Published: 2023

Journal Articles

Outcomes of Patients with B-ALL with Concomitant BCR::ABL1 and CRLF2 Rearrangements

Emmanuel Almanza Huante, Elias Jabbour, Marina Konopleva, Cesar Nunez, Sergej Konoplev, Nicholas Short, Naveen Pemmaraju, Fatima Zahra Jelloul, Guilin Tang, Hagop Kantarjian, Nitin Jain

Blood (2022) 140 (Supplement 1): 3178–3180.

https://doi.org/10.1182/blood-2022-169370

Published: 2022

Journal Articles

Uproleselan Added to Cladribine Plus Low Dose Cytarabine (LDAC) in Patients with Treated Secondary Acute Myeloid Leukemia (TS-AML)

Emmanuel Almanza Huante, Hagop Kantarjian, Kelly S. Chien, Courtney D. DiNardo, Nicholas Short, Abhishek Maiti, Guillermo Montalban-Bravo, Naval Daver, Jitesh D. Kawedia, Kayleigh Bowie, Sherry A. Pierce, Farhad Ravandi, Marina Konopleva, Guillermo Garcia-Manero, Tapan M. Kadia

Blood (2022) 140 (Supplement 1): 3344–3346.

https://doi.org/10.1182/blood-2022-169670

Published: 2022

Journal Articles

Improved Outcomes with Low-Dose Inotuzumab and Mini-Hyper-CVD Followed By Blinatumomab Consolidation in Relapsed-Refractory Acute Lymphoblastic Leukemia: Results of a Phase II Study

Blood (2022) 140 (Supplement 1): 11698–11701.

https://doi.org/10.1182/blood-2022-170049

Published: 2022

Journal Articles

Over-Expression of CRLF2 By Flow Cytometry (FC) Impacts on Overall Survival (OS) in Mexican Patients with Acute Lymphoblastic Leukemia (ALL)

Emmanuel Almanza Huante, Juan Rangel-Patiño, Rosana Daniela Córdova-Serrano, Karla Adriana Espinosa, Roberta Demichelis

Blood (2021) 138 (Supplement 1): 3367.

https://doi.org/10.1182/blood-2021-153309

Published: 2021

Journal Articles

Central Nervous System (CNS) Involvement in Adult Acute Lymphoblastic Leukemia (ALL) Assessed Solely By Flow Cytometry Has an Adverse Impact on Survival

Rosana Daniela Córdova-Serrano, MD, Emmanuel Almanza Huante, MDMD, Emmanuel Mártinez-Moreno, MD, Areli Hérnandez-Alcántara, MD, Emmanuel Fernández-Sánchez, MD, Andres Gomez-De Leon, MD, Karla Adriana Espinosa, MD

Blood (2020) 136 (Supplement 1): 2–3.

https://doi.org/10.1182/blood-2020-142892

Published: 2020

Journal Articles

Low Prevalence of T-Cell Lymphoblastic Leukemia/Lymphoma in an Adult Hispanic Population: A Report of the Acute Leukemia Working Group (GTLA)

Luis Felipe Rubalcava-Lara, MD, Emmanuel Almanza Huante, MDMD, Roberta Demichelis, MD, Juan Rangel-Patiño, MD, Andres Gomez-De Leon, MD, Gerardo A De la rosa-Flores, MD, Alvaro Cabrera Garcia, katheryn Betsabe Garzon, MD, Karla Adriana Espinosa, MD

Blood (2020) 136 (Supplement 1): 5–6.

https://doi.org/10.1182/blood-2020-142639

Published: 2020

Journal Articles

Pediatric-Inspired Regimens Are Associated with Better Outcomes When Compared with Hypercvad in Hispanic Adolescents and Young Adults with Acute Lymphoblastic Leukemia

Roberta Demichelis, MD, Karla Adriana Espinosa, MD MSc, Juan Rangel-Patiño, MD, Emmanuel Almanza, MD, Ana Cooke, MD

Blood (2019) 134 (Supplement_1): 3877.

https://doi.org/10.1182/blood-2019-125370

Published: 2019

NARROW

Phase Ib/II Study of CPX-351 in Combination with Venetoclax in Patients with Newly Diagnosed, High Risk Acute Myeloid Leukemia

Final Results of a Phase II Study of Uproleselan Combined with Cladribine and Low-Dose Cytarabine for Patients with Treated Secondary Acute Myeloid Leukemia (ts-AML)

Performance of the Molecular International Prognostic Scoring System (IPSS-M) in Myelodysplastic Syndromes Treated with Hypomethylating Agent-Based Therapy: A Multicenter Analysis

Combination of CPX-351 and Gemtuzumab Ozogamicin (GO) in Relapsed Refractory (R/R) Acute Myeloid Leukemia and Post Hypomethylating Agent (HMA) Failure High-Risk Myelodysplastic Syndrome (HR-MDS)

Patterns of Relapse Following Venetoclax-Based Therapies of Differing Intensity in Acute Myeloid Leukemia

Clinicopathologic Predictors of Hypomethylating Agent Failure in Patients with Myelodysplastic Syndromes

Patterns of Relapse in Patients with Acute Myeloid Leukemia (AML) Treated with Venetoclax-Containing Regimens

NPM1-Mutated Myeloid Neoplasms: Updated Outcomes with High-Intensive Chemotherapy Regardless of the Blast Percentage

Clinical Characteristics and Outcomes of Therapy-Related Chronic Myelomonocytic Leukemia: Analysis of a Large Cohort

Performance of the Molecular International Prognostic Scoring System (IPSS-M) in Hypomethylating Agent-Treated Patients with Myelodysplastic Syndromes

Uproleselan Added to Cladribine Plus Low Dose Cytarabine (LDAC) in Patients with Treated Secondary Acute Myeloid Leukemia (TS-AML)

Fludarabine, Cytarabine (ARA-C) and Pegylated Erwinase (PEGCRISANTASPASE) in Patients with Relapsed or Refractory Leukemia

Outcomes of Patients with B-ALL with Concomitant BCR::ABL1 and CRLF2 Rearrangements

Uproleselan Added to Cladribine Plus Low Dose Cytarabine (LDAC) in Patients with Treated Secondary Acute Myeloid Leukemia (TS-AML)

Improved Outcomes with Low-Dose Inotuzumab and Mini-Hyper-CVD Followed By Blinatumomab Consolidation in Relapsed-Refractory Acute Lymphoblastic Leukemia: Results of a Phase II Study

Over-Expression of CRLF2 By Flow Cytometry (FC) Impacts on Overall Survival (OS) in Mexican Patients with Acute Lymphoblastic Leukemia (ALL)

Central Nervous System (CNS) Involvement in Adult Acute Lymphoblastic Leukemia (ALL) Assessed Solely By Flow Cytometry Has an Adverse Impact on Survival

Low Prevalence of T-Cell Lymphoblastic Leukemia/Lymphoma in an Adult Hispanic Population: A Report of the Acute Leukemia Working Group (GTLA)

Pediatric-Inspired Regimens Are Associated with Better Outcomes When Compared with Hypercvad in Hispanic Adolescents and Young Adults with Acute Lymphoblastic Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only